Our Products

Platform Direction

The Company’s AntiSense molecular diagnostic platform is being developed for use at Point of Care (POC) to test on-site, and In Home (HUT) for a wide range of viral and other diseases.

The Company’s first products are AntiSense molecular diagnostic test kits that accurately, quickly and affordably detect respiratory infections, including Covid-19 in less than 5 minutes.

Applications & Uses

Deployed at the point of entry of high traffic venues such as airports, shopping malls, office buildings, sporting venues, manufacturing plants, hospitals, pharmacies, nursing and long-term care homes the AntiSense POC molecular diagnostic test kit will contribute to safe reopening of the economy. The AnitSense HUT molecular diagnostic test kit will further allow for quick, easy, and accurate in home self-testing, allowing the economy to remain open.

Airports
Office Buildings
Shopping Malls
Manufacturing Sites
Hospitals
Nursing/ Care Homes
Sporting Venues
Pharmacies

Point of Care Diagnostic

Insert patient sample swab into cartridge, close cap of cartridge, insert cartridge into instrument reader to individually run diagnostic test.  Once test cycle completes the result will automatically be sent to electronic devices - smart phones, Ipads or computers.

Investors

We have established a world class executive leadership team, Board of Directors and Board of Advisors, with experience in healthcare, life sciences, medical devices, diagnostics, biotechnology, nanomedicine, drug delivery, and pharmaceuticals. Our financial advisors have decades of global experience in investment banking in the private and public sector.

LEARN MORE

RNA Disease Diagnostics Secures Exclusive License to Ground-Breaking RNA-Based Molecular Lateral Flow Assay Technology

November 9, 2021

RNA Disease Diagnostics, Inc. (“RNADD” or the “Company”), a company developing a best-in-class molecular diagnostics platform to democratize point-of-care and home-use infectious disease detection, announced today that it has secured an exclusive global license to a rapid ribonucleic acid (“RNA”)-based molecular Lateral Flow Assay (“LFA”) technology jointly owned by the University of Maryland, Baltimore (“UMB”) and the University of Maryland, Baltimore County (“UMBC”).

Read More

Board-Certified Internist and Renowned Professional Sports Team Physician, Dr. Michael S. Farber, Joins RNA Disease Diagnostics’ Advisory Board

September 2, 2021

RNA Disease Diagnostics, Inc. (RNADD), a company developing a best-in-class molecular diagnostics platform to democratize point-of-care and home-use infectious disease detection, announced today the appointment of Michael S. Farber, M.D. to its Advisory Board.

Read More